SABCS

News

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

News

Roche delivers its data reveal for adjuvant giredestrant

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

SABCS: Pharmas show their working in HR+/HER2- breast cancer

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the cha

News

Radiology technician examens mammography test on location

SABCS: New ADC from AZ and Daiichi shows promise in breast c...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu is already making waves in breast cancer, and clinical results presented at the San Antonio Breast Cancer Symposium (S

News

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

The results of the SERENA-2 trial of AstraZeneca’s oral selective estrogen receptor degrader (SERD) camizestrant, reported at the SABCS congress this week, could restore confidence in the m

Pfizer makes first-line case for Tukysa in breast cancer

Roche delivers its data reveal for adjuvant giredestrant

SABCS: Pharmas show their working in HR+/HER2- breast cancer

SABCS: New ADC from AZ and Daiichi shows promise in breast c...

SABCS: AZ’s oral SERD data may “relaunch enthusiasm” for cla...

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

SABCS

Editor's Picks